title: Effect of probucol on intracellular pH and proliferation of human vascular endothelial cells.
abstract: We investigated the effect of probucol on the intracellular pH ([pH]i) and proliferation of human umbilical vein endothelial cells (HUVEC), as well as their production of prostacyclin (PGI2). The addition of probucol produced a biphasic shift in [pH]i, with a brief initial acidification followed by a rapid alkaline shift. After pretreatment with EGTA, the initial decrease in [pH]i was abolished, and the subsequent increase was inhibited. After pretreatment with amiloride, only the increase of [pH]i was abolished. These results suggest that the probucol-induced increase of [pH]i was mainly dependent on Na+/H+ exchange and partly on extracellular Ca2+. In contrast, the addition of LDL produced a decrease of [pH]i. Under Ca2+-free condition, [pH]i was further decreased by LDL. In cells pretreated with amiloride, however, [pH]i was not further decreased by LDL. It was found that probucol promoted cell proliferation, and LDL inhibited cell proliferation. Addition of probucol also enhanced prostacyclin generation by HUVEC. This enhancement of PGI2 generation resulted from increased release of Ca2+ from the storage sites, due not only to increased production of inositol 1,4,5-triphosphate (IP3) but also to the increase of [pH]i. These findings may help to explain the antiatherosclerotic action of probucol.
authors.affiliation: Second Department of Medicine, Kyoto Prefectural University of Medicine, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Komatsu
authors.forename: S
authors.initials: S
authors.lastname: Sawada
authors.forename: T
authors.initials: T
authors.lastname: Tamagaki
authors.forename: Y
authors.initials: Y
authors.lastname: Tsuda
authors.forename: Y
authors.initials: Y
authors.lastname: Kono
authors.forename: T
authors.initials: T
authors.lastname: Higaki
authors.forename: H
authors.initials: H
authors.lastname: Imamura
authors.forename: Y
authors.initials: Y
authors.lastname: Tada
authors.forename: S
authors.initials: S
authors.lastname: Yamasaki
authors.forename: A
authors.initials: A
authors.lastname: Toratani
authors.forename: T
authors.initials: T
authors.lastname: Sato
authors.forename: N
authors.initials: N
authors.lastname: Akamatsu
authors.forename: H
authors.initials: H
authors.lastname: Tsuji
authors.forename: M
authors.initials: M
authors.lastname: Nakagawa
mesh_terms: D000584:Amiloride / Q000494:pharmacology; D000924:Anticholesteremic Agents / Q000494:pharmacology*; D002118:Calcium / Q000378:metabolism; D002455:Cell Division / Q000187:drug effects*; D002478:Cells, Cultured; D004533:Egtazic Acid / Q000494:pharmacology; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D011464:Epoprostenol / Q000378:metabolism; D006801:Humans; D006863:Hydrogen-Ion Concentration / Q000187:drug effects; D008077:Lipoproteins, LDL / Q000494:pharmacology; D011341:Probucol / Q000494:pharmacology*; D013936:Thymidine / Q000378:metabolism; D014471:Umbilical Veins
chemical_list: D000924:Anticholesteremic Agents; D008077:Lipoproteins, LDL; D004533:Egtazic Acid; D000584:Amiloride; D011464:Epoprostenol; D011341:Probucol; D002118:Calcium; D013936:Thymidine